| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T272 |
128-177 |
Sentence |
denotes |
Open-label RCT (NCT04324021, not yet recruiting). |
| T273 |
178-224 |
Sentence |
denotes |
Primary endpoint: treatment success at day 15. |
| T274 |
225-426 |
Sentence |
denotes |
• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. |
| T275 |
427-476 |
Sentence |
denotes |
Open-label RCT (NCT04330638, not yet recruiting). |
| T276 |
477-544 |
Sentence |
denotes |
Primary endpoint: time to clinical improvement (follow-up 15 days). |
